COMMUNIQUÉS West-GlobeNewswire

ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
06/08/2026
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
06/08/2026
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented [...]
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second [...]
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b [...]
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
06/08/2026
Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment Successful limited launch of the power liposuction handpiece for the AYON platform [...]
CVRx Reports Second Quarter 2026 Financial and Operating Results
06/08/2026
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Oculis Reports Q2 2026 Financial Results and Provides Company Update
06/08/2026
Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following [...]
Oculis Reports Q2 2026 Financial Results and Provides Company Update
06/08/2026
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential [...]
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026 to [...]
TerrAscend Reports Second Quarter 2026 Financial Results
06/08/2026
Q2 2026 Net Revenue of $67.1 Million, Up Sequentially and Year-Over-Year Q2 2026 Gross Profit Margin of 54.0%, Up 120 Basis Points Sequentially and 290 Basis Points Year-Over-Year Q2 2026 Net Cash Provided from [...]
Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
06/08/2026
Record Second-Quarter Net Revenue Growth of 36% to $6 million; Core Programmatic Revenue Grew by 27% Year Over Year SOUTH ORANGE, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water [...]
Profound Medical Reports Second Quarter 2026 Financial Results
06/08/2026
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and [...]
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
06/08/2026
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported [...]
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
06/08/2026
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in [...]
Globus Medical Reports Second Quarter 2026 Results
06/08/2026
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second [...]
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
06/08/2026
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition [...]
Flyte Achieves Record Revenues in July
06/08/2026
July 2026 Revenue Increased 102% sequential July Over June to Approximately $640,000 Retail Platform, Strategic Partnerships and Influencer Marketing Fuel Accelerating Growth FORT MILL, S.C., Aug. 06, 2026 (GLOBE [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2026
06/08/2026
Lasmé-cel: phase 2 pivotale dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Lasmé-cel a reçu le statut RMAT de la FDA Résultats complets de phase 1 pour lasmé-cel présentés au congrès annuel de l’EHA 2026 [...]
Cellectis Reports Financial Results for the Second Quarter 2026
06/08/2026
Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected in [...]

Pages